ABVC BioPharma Highlights Safety Profile of Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the US.

ABVC BioPharma highlighted the safety profile of its plant-based ADHD candidate, ABV-1505, amid growing concerns about psychiatric polypharmacy in the US. ABV-1505 has demonstrated a favorable tolerability profile in early clinical studies with no drug-related serious adverse events reported. The company's approach is distinct from traditional stimulant or amphetamine-based therapies, being plant-based, non-stimulant, and not shown to cause addiction or dependency. ABV-1505 has completed a Phase II clinical trial at UCSF, showing statistically significant improvement on ADHD rating scales and no serious safety concerns observed.